Highest-materiality recent filing
Nuvectis Pharma establishes new $200M ATM offering program with Jefferies
Entered Open Market Sale Agreement with Jefferies LLC on Aug 21, 2026, for up to $200M in common stock.
In-licensed ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco; ciprocopan approved in China for PNH in July 2026.
Nuvectis Pharma prices $100M public offering of 5M shares at $20.00 per share
Priced underwritten public offering of 5,000,000 shares at $20.00 per share for gross proceeds of $100 million.
Nuvectis Pharma reduces ATM capacity to $5M and suspends sales under Leerink agreement
On June 29, 2026, Nuvectis lowered the amount available for sale under the Sales Agreement Prospectus to $5 million.
Nuvectis in-licenses ex-China rights to two clinical-stage compounds from Haisco for up to $1.46B
Upfront and near-term payments total up to $40M; potential milestones up to $1.421B plus tiered royalties.
Nuvectis Pharma annual meeting elects director; proxy share count corrected
Proxy mistakenly stated 27,668,036 shares outstanding; correct count is 26,614,628.
Nuvectis Pharma Q1 2026 net loss $6.1M; cash $25.1M; NXP900 Phase 1b data expected summer
Cash and equivalents $25.1M as of March 31, 2026, down from $31.6M at Dec 31, 2025.
Nuvectis Pharma reports FY2025 net loss $26.4M; cash $31.6M; NXP900 program advancing
Net loss $26.4M for FY2025 vs $19.0M in FY2024; includes $6.0M stock-based comp and $2.4M milestone license fees.
Nuvectis Pharma Q3 net loss $7.5M; cash $35.4M; NXP900 Phase 1b underway
Cash $35.4M at Sep 30, 2025, up from $18.5M at Dec 31, 2024; runway into 3Q2027.
Nuvectis Pharma appoints biotech executive Juan Sanchez, MD to Board of Directors
Juan Sanchez, MD appointed to board effective Sept 22, 2025; term expires at 2026 annual meeting.
Nuvectis reports Q2 net loss of $6.3M; NXP900 Phase 1a complete; cash ~$39M proforma
Net loss of $6.3M for Q2 2025 vs $4.4M for Q2 2024; increase driven by NXP900 DDI study and stock-based compensation.
Nuvectis Pharma shareholders elect director, ratify auditor at 2025 annual meeting
Quorum of 14,605,167 shares (61.86%) present out of 23,606,443 outstanding shares.
Nuvectis Pharma establishes $60M ATM with Leerink Partners; terminates prior HC Wainwright program
New ATM agreement with Leerink Partners to sell up to $60M of common stock; 3.0% commission on gross proceeds.
Nuvectis Pharma Q1 2025 net loss $5.3M; cash $29.9M; NXP900 Phase 1b advancing
Cash and equivalents $29.9M as of Mar 31, 2025, up from $18.5M at Dec 31, 2024, driven by $14.0M net public offering proceeds.
Nuvectis Pharma reports FY2024 net loss of $19.0M; follow-on offering extends cash runway into 2027
Cash and cash equivalents $18.5M as of Dec 31, 2024, down from $19.1M; net loss $19.0M, vs $22.3M in 2023.
Nuvectis Pharma prices $13.5M public offering at $5/share; full over-allotment exercised
Priced 2.7M shares at $5.00 for $13.5M gross; underwriter fully exercised over-allotment of 405k shares, total gross $15.5M, net ~$14.4M.
Nuvectis Pharma Q3 2024 net loss $4.2M; NXP800 data update expected November
Net loss $4.2M in Q3 2024 vs $5.9M Q3 2023; R&D expenses $2.8M vs $4.5M.
Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in ARID1a-deficient ovarian cancers
FDA granted Orphan Drug Designation for NXP800 for treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
Nuvectis Q2 2024 net loss narrows to $4.4M; progressing NXP800 and NXP900 trials
Cash $18.1M at June 30, 2024, down $1.4M from March 31, 2024; net loss $4.4M vs $5.8M YoY.
Nuvectis Pharma stockholders re-elect directors and ratify auditor at 2024 annual meeting
Kenneth Hoberman elected Class II director with 8,026,155 votes for, 809,797 against.
Nuvectis Q1 2024 net loss $4.2M; cash $19.5M; NXP800 Phase 1b data encouraging
Net loss $4.2M in Q1 2024 vs $4.0M in Q1 2023; cash $19.5M (up from $19.1M in Dec 2023).
Nuvectis Pharma FY2023 net loss $22.3M; cash $19.1M; NXP800 data update expected March 2024
Cash and cash equivalents $19.1M at Dec 31, 2023, down from $20.0M at Dec 31, 2022.
Nuvectis reports Q3 2023 net loss of $5.9M; cash $22.1M; NXP800 orphan drug status
Cash and investments $22.1M at Sep 30, 2023, up from $20.0M at Dec 31, 2022.
Nuvectis Pharma initiates Phase 1a trial of NXP900 for advanced solid tumors
Phase 1a dose-escalation study evaluates safety, tolerability, and PK of NXP900 in advanced solid tumor patients.
Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in cholangiocarcinoma
FDA granted Orphan Drug Designation to NXP800 for cholangiocarcinoma.
Nuvectis Q2 net loss $5.7M; cash $24.6M; NXP900 IND cleared, Phase 1a expected Q3 2023
Cash $24.6M at June 30, 2023, up from $20.0M at Dec 31, 2022, enough into H1 2025.
Nuvectis Pharma reports $24.5M cash, runway into H1 2025
Cash and equivalents of $24.5M at June 30, 2023, up ~$9.0M from March 31, 2023.
Nuvectis Pharma shareholders approve equity plan amendment increasing shares by 1M
Stockholders approved amendment to Global Equity Incentive Plan (2021) adding 1,000,000 shares and annual evergreen from 2024-2033.
Nuvectis Pharma gets FDA clearance to begin Phase 1 trial for NXP900
FDA cleared IND for NXP900, including Phase 1 clinical trial protocol.
Nuvectis Pharma Q1 net loss $4.0M; initiates Phase 1b for NXP800 in ovarian cancer
Cash $15.5M as of March 31, 2023 vs $20.0M at Dec 31, 2022; net loss $4.0M (Q1 2023) vs $2.9M (Q1 2022).
Nuvectis Pharma FY2022 net loss $19.1M; cash $20M; NXP800 Fast Track; NXP900 IND expected 1H23
Cash and short-term investments $20.0M at Dec 31, 2022, up from $5.7M.
Nuvectis Pharma reports Q3 net loss $5.9M; provides NXP800/NXP900 clinical updates
Net loss $5.9M for Q3 2022 vs $4.7M in Q3 2021; cash $23.6M as of Sep 30, 2022.
Nuvectis reports Q2 2022 net loss of $3.6M; cash $13.6M; pipeline advances
Cash and investments $13.6M at June 30, 2022, up from $5.7M at Dec 31, 2021, driven by IPO.
Nuvectis Pharma raises ~$15.9M in private placement of common stock and warrants
Gross proceeds $15.9M from sale of 1,924,689 shares or pre-funded warrants at $8.25 per share plus preferred investment options.
Nuvectis Pharma Q1 net loss $2.9M; cash $16.7M; NXP800 Phase 1 dose escalation ongoing
Net loss of $2.9M for Q1 2022, including $0.2M non-cash expense.
Nuvectis Pharma FY2021 net loss $12.9M; IPO raised $16M; CFO replaced
Net loss of $12.9M for FY2021, including $7.0M upfront license payments and $1.9M non-cash equity compensation.
Gross proceeds of $16M from sale of 3.2M shares at $5.00; expected close Feb 8, 2022.
Michael Carson, who recently joined Nuvectis as Vice President of Finance, is replacing Uri Ben-Or
Uri Ben-Or who served as the Company's Interim Chief Financial Officer.
Max materiality 0.85 · Median 0.60 · Most common event earnings